Bookbuilding IPO | ₹12 Cr | Listed at BSE SME | Tue, May 12, 2026 - Thu, May 14, 2026
| Category | QIB | NII | Retail | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor Investor | Total QIB | Above ₹10L | Below ₹10L | Total NII | |||
| Allocation (No. of shares) | 5,40,000 | 7,32,000 | 12,72,000 | 2,58,000 | 1,32,000 | 3,90,000 | 9,00,000 | 25,62,000 |
| Allotment price (₹) | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| No. of applications | 67 | 2 | 69 | 20,419 | 13,470 | 33,889 | 1,31,130 | 1,65,088 |
| No. of shares applied | 9,69,93,000 | 9,36,000 | 9,79,29,000 | 51,84,99,000 | 13,06,35,000 | 64,91,34,000 | 78,67,80,000 | 1,53,38,43,000 |
| Amount collected (₹ Cr.) | 417.07 Cr | 4.02 Cr | 421.09 Cr | 2,229.55 Cr | 561.73 Cr | 2,791.28 Cr | 3,383.15 Cr | 6,595.52 Cr |
| No. of times subscribed | 179.62 | 1.28 | 76.99 | 2009.69 | 989.66 | 1664.45 | 874.20 | 598.69 |
| No. of shares allotted | 5,40,000 | 7,32,000 | 12,72,000 | 2,61,000 | 1,29,000 | 3,90,000 | 9,00,000 | 25,62,000 |
| Amount allotted (₹ Cr.) | 2.32 Cr | 3.15 Cr | 5.47 Cr | 1.12 Cr | 0.55 Cr | 1.68 Cr | 3.87 Cr | 11.02 Cr |
| No. of allottees | 56 | 2 | 58 | 29 | 14 | 43 | 150 | 251 |
Goldline Pharmaceutical IPO is a public issue of 0.26 Cr equity shares. The issue offers 0.09 Cr shares to retail investors, 0.13 Cr shares to qualified institutional buyers, and 0.04 Cr shares to non-institutional investors.
| Category | Shares Offered | Amt (₹ Cr.) | Size (%) |
|---|---|---|---|
| Market Maker | 1,38,000 | 0.59 | 5.11% |
| QIB | 12,72,000 | 5.47 | 47.11% |
| Anchor | 7,32,000 | 3.15 | 27.11% |
| QIB (Ex Anchor) | 5,40,000 | 2.32 | 20.00% |
| NII* | 3,90,000 | 1.68 | 14.44% |
| bNII (> ₹10L) | 2,58,000 | 1.11 | 9.56% |
| sNII (< ₹10L) | 1,32,000 | 0.57 | 4.89% |
| Retail | 9,00,000 | 3.87 | 33.33% |
| Total | 27,00,000 | 11.61 | 100% |
A total of 7,32,000 shares at a price of Rs 43 per share will be allotted to the anchor investors.
| Bid Date | May 11, 2026 |
| Price | ₹43.00 |
| % of QIBs | 57.55% |
| Shares Locked (30 Days) | 3,66,000 |
| Shares Locked (90 Days) | 3,66,000 |
| # | Anchor | Group Entity | Shares Allotted | Amt (₹ cr.) | % Allocated | % Allotment of Issue |
|---|---|---|---|---|---|---|
| 1 | UPSURGE OPPORTUNITIES FUND I | UPSURGE | 3,66,000 | 1.57 | 50.00 | 13.56 |
| 2 | VIKASA INDIA EIF I FUND-SHARE CLASS P | VIKASA | 3,66,000 | 1.57 | 50.00 | 13.56 |
| 7,32,000 | 3.15 | 100 | 27.11 | |||
📊 Historic report - IPOs Anchor Investors Investment & Performance
The Goldline Pharmaceutical IPO is subscribed 600.53x as of May 14, 2026 18:54.
| Investor Category | Subscription (times) |
|---|---|
| Qualified Institutional | 180.22x |
| Non Institutional | 1662.04x |
| Retail Individual | 881.15x |
| Total Subscription | 600.53x |
An investor can apply in Goldline Pharmaceutical IPO online via bank (using ASBA) or the broker (using UPI). The Goldline Pharmaceutical IPO shares are offered online only.
The Goldline Pharmaceutical IPO is subscribed 600.53x times as of May 14, 2026 18:54.
The Goldline Pharmaceutical IPO allotment status is expected on or around Friday, May 15, 2026. Visit Goldline Pharmaceutical IPO allotment status to check.
The Goldline Pharmaceutical IPO listing date is May 19, 2026. The equity share of Goldline Pharmaceutical IPO will list on BSE SME.
Visit Goldline Pharmaceutical IPO subscription status page for real-time bidding information about Goldline Pharmaceutical IPO.
| IPO opens On | Tuesday, May 12, 2026 |
| IPO Closes On | Thursday, May 14, 2026 |
| Finalisation of Basis of Allotment | Friday, May 15, 2026 |
| Initiation of Refunds | Monday, May 18, 2026 |
| Credit of Shares to Demat Account | Monday, May 18, 2026 |
| IPO Listing Date | Tuesday, May 19, 2026 |
| IPO Details |
| IPO Recommendations |
| IPO Live Subscription |
| IPO Live News |
| IPO Allotment Status |
| IPO Basis of Allotment Document |
| IPO FAQs |
